社区

Endeavor BioMedicines recently announced that its IPF candidate taladegib (ENV-101) met the primary endpoint and multiple key secondary endpoints in a Phase IIb study. These results highlight the potential of taladegib in the treatment of idiopathic pulmonary fibrosis (IPF) and further validate the strategy of targeting the Hedgehog (Hh) signaling pathway. Current standard-of-care therapies, nintedanib and pirfenidone, can only slow the decline in lung function and do not halt or reverse disease progression. Taladegib, by inhibiting aberrantly activated Hedgehog signaling, reduces pulmonary fibrosis and improves lung function.

As a Hedgehog pathway inhibitor with the same target, GT1708F also has therapeutic potential for IPF. It inhibits SMO protein activity, thereby affecting Hh pathway activity and the expression of downstream related proteins. Hh pathway reactivation is a characteristic of fibrotic lung tissue in IPF and influences fibroblast migration and proliferation. Notably, Hedgehog inhibitors not only hold promise for the treatment of IPF but also have development value in other fibrotic diseases. In in vitro studies, GT1708F demonstrated superior inhibitory activity against the Hh pathway compared with taladegib. In in vivo IPF models, GT1708F effectively ameliorated pulmonary fibrosis and was superior to taladegib at the same dose. Currently, GT1708F has completed a phase I clinical trial in China for hematologic malignancies and has been authorized to initiate  a phase II clinical trial in China and a phase I clinical trial in the US for IPF.

As a great health company in innovative topical dermatological drugs, we are open to global collaborative development of GT1708F and look forward to in-depth discussions with more partners on collaboration models such as rights licensing, including but not limited to license-out and the formation of a NewCo. We hope to work together with partners to accelerate clinical development and bring innovative therapies to patients worldwide as soon as possible.

About Kintor Pharmaceutical Limited

Founded in 2009, Kintor Pharmaceutical Limited focuses on developing and commercializing potential "first-in-class" and "best-in-class" innovative drugs and functional cosmetics, aiming to be a leading enterprise in such areas, and establish a “troika” business model formed by R&D business of innovative topical drugs, B2B business of functional cosmetic raw materials and B2C business of functional cosmetic products. After several years' development, the Company has developed diverse product pipeline built on dermatology related diseases. The products cover diseases with high incidence rate globally and extend to functional cosmetics, which can meet the needs of clinical dermatology and cosmetics consumers worldwide. Kintor Pharma's layout includes innovative small molecule and biologic drugs, consisting of five productsunder clinical development and several preclinical research programs. Kintor Pharma has been granted more than 100 patents worldwide. On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK. For more information, please visit www.kintor.com.cn.